Background {#Sec1}
==========

Coronary artery disease (CAD) is generated by multi-factors including both genetic and traditional risk factors \[[@CR1]--[@CR12]\]. Acknowledged risk factors for CAD include age, male gender, family history of premature coronary artery disease, diabetes mellitus (DM), hypertension, dyslipidemia, obesity, cigarettes smoking, drinking and physical inactivity \[[@CR13]\]. However, individual variation in the severity of lesions and long-term prognosis has been observed. Patients with similar lesions and receiving similar treatment may become stable or progress. On the contrary, a small proportion of CAD patients lack classical risk factors. Therefore, researchers think that genetic factors not only contribute to the occurrence of atherosclerosis but also to the progression of atherosclerosis, along with classical risk factors \[[@CR14]--[@CR16]\]. Data of susceptible gene polymorphisms related to the progression of coronary atherosclerosis in Chinese population is still limited \[[@CR7], [@CR8]\]. Therefore, we conducted this study to examine several susceptible gene polymorphisms in a group of patients with three-vessel disease (TVD), a severe type of CAD, who suffered from progression of coronary atherosclerosis, presented as 1-year adverse cardiac and cerebrovascular events during long-term follow-up. We analyzed the differences of variant allele frequencies between this "rapidly worsening" group of patients and non-CAD controls to explain the possible genetic effects on progression of TVD.

Methods {#Sec2}
=======

Ethical statement {#Sec3}
-----------------

Ethical approvals were obtained from the Fuwai Hospital Research Ethics Committees. The Institutional Review Board approved the study protocol and all patients signed written informed consent before the intervention, including full set of risk-informed consent and information use consent for scientific purposes.

A TVD cohort with long-term follow-up {#Sec4}
-------------------------------------

A total of 8943 consecutive cases diagnosed as TVD by coronary angiography were prospectively enrolled from April 2004 to February 2011 in Fuwai hospital, Chinese Academy of Medical Sciences (Beijing, China). TVD was defined as angiographic stenosis of ≥50% in all three main epicardial coronary arteries, including left anterior descending, circumflex and right coronary artery, with or without left main artery involved. There were no exclusion criteria. Patients received optimizing drug therapy (ODT) alone, percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) according to contemporary practice guidelines and their preferences. Patients who received PCI or CABG were also treated with ODT according to guidelines. Clinical baseline and procedural data of all participants were collected into a database by independent clinical research coordinators. Follow-up pattern included telephone interview, follow-up letter and clinic visit. The last follow-up was finished in 2016, with the response rate of 80.6%. All events defined by study protocol were carefully verified by an independent group of clinical physicians \[[@CR17]\].

Definitions and study population {#Sec5}
--------------------------------

Major adverse cardiac and cerebrovascular events (MACCE) included all-cause death, acute myocardial infarction (AMI), stroke, repeat revascularization and readmission. Readmission only referred to ischemia-driven readmission and did not include elective readmission for complete revascularization. A total of 512 patients who suffered from1-year MACCE were selected as MACCE group, considered as rapidly worsening atherosclerotic cases. Because part of samples did not pass the deoxyribonucleic acid (DNA) quality test due to repeated freeze-thaw or experimental exhaustion, 342 cases were finally analyzed in MACCE group.

Control group {#Sec6}
-------------

Non-CAD control group was enrolled with almost 1:1 ratio. Inclusion criteria including age ≥ 40 years, no CAD history, no manifestation of myocardial ischemia or infarction on electrocardiogram, no regional wall motion abnormalities, wall thinning, ventricular enlargement or lowered ejection fraction on echocardiography, or coronary stenosis \< 50% observed on multi-slice spiral CT coronary angiography or coronary angiography.

DNA database and SNP genotyping {#Sec7}
-------------------------------

Blood samples of MACCE and control groups were collected after enrollment at hospital admission. A blood sample database was created for DNA extraction. Human genomic DNA was extracted using a standard method as described by Chi S. et al. \[[@CR18]\]. Single nucleotide polymorphism (SNP) genotyping was performed using a custom design 48-Plex SNPscan™ Kit (Cat\#: G0104; Genesky Biotechnologies Inc., Shanghai, China). The assay was based on double ligation and multiplex fluorescence polymerase chain reaction (PCR). For the sake of clarity, a brief description of the genotyping protocol is included. 100--200 ng of DNA sample was denatured at 98 °C for 5 min in a 10-ml reaction containing 1× DNA lysis buffer and then mixed well with a 10-ml ligation solution composed of 2 ml of 103 ligase buffer, 0.5 ml of ligase, 1 ml of probe mix, and 7.5 ml of Milli-Q water. The ligation reaction was carried out in an ABI2720 thermal cycler. Two 48-plex fluorescence PCR reactions were performed for each ligation product. PCR reactions were prepared in 20 ml of a mixture containing 1× PCR master mix, 1 ml of primer mix set A or set B, and 1 ml of ligation product. PCR products were separated and detected by capillary electrophoresis in an ABI3730XL sequencer. Raw data were analyzed according to information obtained for the labeling dye color and fragment size of the allele-specific ligation-PCR product. Subject's case or control status was blinded during genotyping. For quality control, repeated analyses were performed to ensure the reproducibility of the results by randomly choosing 4% of samples with high DNA quality.

Candidate genes {#Sec8}
---------------

Overall, 34 tag or hot SNPs on *CDKN2B-AS1, ABO, ADAMTS7, ADAMTS13, IL-18,* and *PECAM1* genes were selected as candidate SNPs. Relevant data of SNPs referred to genome wide association studies (GWAS) in the Han population. Data of susceptible genes of CAD referred to the HapMap database (Data Rel 27 Phase II + III, Feb09, on NCBI B36 assembly, dbSNP b126). Minor allele frequency (MAF) was ≥0.05, r^2^ \> 0.8. An online software (<http://hapmap.ncbi.nlm.nih.gov/cgi-perl/gbrowse/hapmap27_B36/#search>) was used for tag SNP selection. Thirty-four candidate SNPs were rs974336, rs3217986, rs1063192, rs3217992, rs9632884, rs10757274, rs1333042, rs1333049 and rs4977574 on *CDKN2B-AS1* gene (9p21.3); rs3743057, rs4887112, rs922693, rs11072806 and rs3825807 on *ADAMTS7* gene; rs8176747, rs643434, rs8176668, rs500499, rs8176731, rs2073824, rs8176694, rs8176740 and rs8176707 on *ABO* gene; rs3780809, rs1055432, rs671410, rs652600 and rs4962153 on *ADAMTS13* gene; rs549908, rs5744280 and rs360722 on *IL-18* gene; rs668 (rs281865545), rs12953 and rs1131012 on *PECAM1* gene.

Statistical analysis {#Sec9}
--------------------

Data statistics was applied using SPSS 22.0 (IBM Corp., Armonk, New York, USA). Student's t-tests were used to compare continuous variables while Chi-square tests were applied to compare categorical variables between the two groups. SNP association analysis was applied in three allele models, dominant, recessive and codominant model, using Chi-square tests to compare variant allele frequency of each SNP between the two groups. Multivariate logistic regression analysis was conducted to evaluate the association between variant allele frequencies and adverse outcome. The results were reported as odds ratios (ORs) with 95% confidence intervals (95% CIs). Variables included in the multivariable model were those showed significant differences between the two groups in univariate analysis (*P* \< 0.05). All analyses were two-sided, and statistical significance was defined as *P* \< 0.05. Tendency of significant difference was judged when 0.05 \< *P* \< 0.1.

Results {#Sec10}
=======

Baseline data {#Sec11}
-------------

Compared with control group, patients in MACCE group were presented with older age, more male, more comorbidities, higher inflammation markers (white blood cell count and high-sensitivity C-reactive protein level), lower hemoglobin, higher alanine transaminase and serum creatinine, higher fasting blood sugar level, lower high-density lipoprotein cholesterol level and low-density lipoprotein cholesterol level (Table [1](#Tab1){ref-type="table"}). Table 1The baseline clinical characteristicsMACCE group (*n* = 342)Non-CAD group (*n* = 344)*P-*valueAge, year62.8 ± 10.250.5 ± 11.5\< 0.0001Male, %270 (78.9)198 (57.6)\< 0.0001BMI, kg/m^2^25.7 ± 3.225.3 ± 3.10.147Hypertension, %241 (70.5)44 (12.8)\< 0.0001DM, %134 (39.2)14 (4.1)\< 0.0001Hyperlipidemia, %209 (61.1)25 (7.3)\< 0.0001Stroke, %56 (16.4)1 (0.3)\< 0.0001PVD, %31 (9.1)0 (0.0)\< 0.0001Smoking history, %201 (58.8)64 (18.6)\< 0.0001WBC, \*10^9^/L7.21 ± 2.086.25 ± 1.73\< 0.0001Hemoglobin, g/L136.7 ± 14.9144.9 ± 12.3\< 0.0001ALT, IU/L30.2 ± 22.624.2 ± 16.0\< 0.0001Serum creatinine, μmol/L84.5 ± 22.072.6 ± 18.4\< 0.0001Uric acid, μmol/L322.1 ± 88.3332.4 ± 98.20.151Triglyceride, mmol/L1.77 ± 0.941.72 ± 1.190.533Total cholesterol, mmol/L4.61 ± 1.074.68 ± 1.150.389HDL-C, mmol/L1.05 ± 0.241.15 ± 0.32\< 0.0001LDL-C, mmol/L2.56 ± 0.812.87 ± 0.88\< 0.0001FPG, mmol/L6.31 ± 2.325.61 ± 1.23\< 0.0001CK-MB, IU/L19.4 ± 40.914.9 ± 4.50.046Hs-CRP, mg/L3.77 ± 3.622.23 ± 1.57\< 0.0001*ALT* alanine transaminase, *BMI*, body mass index, *CAD* coronary artery disease, *CK-MB* creatine kinase-muscle/brain, *DM* diabetes mellitus, *FPG* fasting plasma glucose, *HDL-C* High-density lipoprotein cholesterol, *Hs-CRP* High-sensitivity C-reactive protein, *LDL-C* Low-density lipoprotein cholesterol, *MACCE* major adverse cardiovascular and cerebrovascular events, *PVD* peripheral vessel disease, *WBC* white blood cell count

Candidate SNP association analysis {#Sec12}
----------------------------------

Of all 34 SNPs on six candidate genes, variant allele frequencies of seven SNPs on *CDKN2B-AS1* showed significant differences between MACCE group and control group in at least one kind of allele model. They were rs1063192, rs10757274, rs1333042, rs1333049, rs3217986, rs4977574 and rs9632884. Among them, variant allele frequencies of rs10757274, rs1333049 and rs4977574 were significantly different between the two groups in all three allele models. *P*-values of six SNPs still had statistical significance after adjusting for the false discovery rate (FDR) using Benjamini-Hochberg (BH) procedure (*Q* \< 0.05). G mutant of rs3217986 was not statistically significant after FDR BH adjustment (*Q* \> 0.05). Variant allele frequencies of two SNPs showed tendency of significance: rs1055432 on *ADAMTS13* gene and rs8176694 on *ABO* gene (0.05 \< *P* \< 0.1). Variant allele frequencies of other SNPs showed no significant difference between the two groups in three models (all *P* \> 0.05) (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}). Table 2Candidate SNP association analysisGeneSNPAllele modelMACCE group (*n* = 342)Non-CAD group\
(*n* = 344)*P-*value**CDKN2B-AS1**rs1063192 A \> GDO AA/GG + GA223/119195/149**0.022**RE GG/GA + AA14/32815/3290.862CO GG/GA/AA14/105/22315/134/1950.066rs10757274 A \> GDO AA/GG + GA74/268112/232**0.001**RE GG/GA + AA94/24865/279**0.008**CO GG/GA/AA94/174/7465/167/112**0.001**rs1333042 G \> ADO GG/AA+GA177/165136/208**0.001**RE AA/GA + GG23/31935/3090.104CO AA/GA/GG23/142/17735/173/136**0.004**rs1333049 G \> CDO GG/CC + GC67/275105/239**0.001**RE CC/GC + GG101/24169/275**0.004**CO CC/GC/GG101/174/6769/170/105**0.001**rs3217986 T \> GDO TT/GG + GT279/63303/41**0.018**RE GG/GT + TT3/3390/3440.082CO GG/GT/TT3/60/2790/41/303**0.023**rs4977574 A \> GDO AA/GG + GA73/269111/233**0.001**RE GG/GA + AA94/24865/279**0.008**CO GG/GA/AA94/175/7365/168/111**0.001**rs9632884 C \> GDO CC/GG + GC192/150152/192**0.002**RE GG/GC + CC26/31625/3190.867CO GG/GC/CC26/124/19225/167/152**0.004ADAMTS13**rs1055432 C \> ADO CC/AA+AC242/99266/78**0.057**RE AA/AC + CC4/3373/3410.695CO AA/AC/CC4/95/2423/75/2660.164**ABO**rs8176694 T \> CDO TT/CC + CT315/25300/40**0.050**RE CC/CT + TT6/33411/3290.219CO CC/CT/TT6/19/31511/29/3000.141*CO* codominant model, *DO* dominant model, *MACCE* major adverse cardiovascular and cerebrovascular events, *RE* recessive model, *SNP* single nucleotide polymorphismTable 3FDR BH adjustmentAllele modelGeneSNP*P-*value*Q-value*Dominant modelCDKN2B-AS1rs13330490.0010.009CDKN2B-AS1rs13330420.0010.009CDKN2B-AS1rs107572740.0010.009CDKN2B-AS1rs49775740.0010.009CDKN2B-AS1rs96328840.0020.009CDKN2B-AS1rs32179860.0180.054CDKN2B-AS1rs10631920.0220.0495Recessive modelCDKN2B-AS1rs13330490.0040.036CDKN2B-AS1rs49775740.0080.036CDKN2B-AS1rs107572740.0080.036Codominant modelCDKN2B-AS1rs13330490.0010.009CDKN2B-AS1rs49775740.0010.009CDKN2B-AS1rs107572740.0010.009CDKN2B-AS1rs96328840.0040.018CDKN2B-AS1rs13330420.0040.018CDKN2B-AS1rs32179860.0230.069*FDR BH* false discovery rate Benjamini-Hochberg*Q*-value = *P*-value\*number of hypothesis testing/rank of *P*-valueNumber of hypothesis testing = number of SNPs detected on one gene

Multivariate logistic regression analysis {#Sec13}
-----------------------------------------

In recessive model, G mutant homozygous of rs9632884 (GG vs. GC + CC) (*OR*: 0.24; 95%*CI*: 0.09--0.65; *P* = 0.005) on *CDKN2B-AS1* was independently associated with decreased risk of MACCE in multivariate logistic regression model. G mutant homozygous of rs1063192 (GG vs. GA + AA) (*OR*: 0.25; 95%*CI*: 0.06--1.00; *P* = 0.05) showed a threshold significance (Table [4](#Tab4){ref-type="table"}). Table 4Multivariate logistic regressionGeneSNPAllele modelOR (95%CI)*P-*valueCDKN2B-AS1rs1063192 A \> GDO AA/GG + GA0.85 (0.45, 1.60)0.613RE GG/GA + AA0.25 (0.06, 1.00)0.05rs10757274 A \> GDO AA/GG + GA0.99 (0.45, 2.05)0.977RE GG/GA + AA0.86 (0.42, 1.74)0.67rs1333042 G \> ADO GG/AA+GA1.00 (0.53, 1.86)0.99RE AA/GA + GG2.14 (0.79, 5.83)0.137rs1333049 G \> CDO GG/CC + GC1.43 (0.69, 2.98)0.338RE CC/GC + GG1.21 (0.60, 2.43)0.593rs3217986 T \> GDO TT/GG + GT1.29 (0.53, 3.14)0.572RE GG/GT + TTrs4977574 A \> GDO AA/GG + GA1.00 (0.48, 2.06)0.989RE GG/GA + AA0.86 (0.42, 1.74)0.67rs9632884 C \> GDO CC/GG + GC0.95 (0.51, 1.78)0.872RE GG/GC + CC0.24 (0.09, 0.65)0.005ADAMTS13rs1055432 C \> ADO CC/AA+AC1.43 (0.72, 2.86)0.307RE AA/AC + CC1.34 (0.03, 64.99)0.882ABOrs8176694 T \> CDO TT/CC + CT0.28 (0.07, 1.14)0.075RE CC/CT + TT0.70 (0.09, 5.53)0.733*CI* confidence interval, *OR* odds ratio, *SNP* single nucleotide polymorphism

Discussion {#Sec14}
==========

Studies on cardiovascular diseases in China (2016) reported that there were estimated 0.29 billion patients with cardiovascular disease (CVD) in China in 2015, of which CAD patients accounted for 11 million. CVD is considered the most important fatal disease and accounted for 42.61 and 45.01% of major causes of death among urban and rural Chinese residents in 2015, respectively. In other words, about two in every five deaths were attributed to CVD \[[@CR1]\]. Traditional risk factors including smoking, obesity, low physical activity, hypertension, hyperlipidemia and DM are considered as the main factors responsible for onset and progression of coronary atherosclerosis \[[@CR4]\]. In recent years, GWAS confirmed that genetic factors also play an important role in occurrence and progression of CAD. It is of great significance to identify the predisposing genes of CAD to understand its pathogenesis, search for new therapeutic targets, establish individualized treatment and evaluate prognosis \[[@CR5]--[@CR8], [@CR13]\].

The most important manifestation of coronary atherosclerosis progression is transformation of stable plaque into vulnerable plaque, leading to acute cardiac or cerebrovascular events. It was reported that cytobands of 9p21.3, 2q36.3, 6q25.1, 1q41, and 1p13.3 were all associated with adverse cardio-cerebrovascular events \[[@CR14]--[@CR16]\]. Therefore, six genes were selected as candidate genes, including *CDKN2B-AS1, ADAMTS7, ABO, ADAMTS13, IL-18, PECAM1*, in terms of references \[[@CR8], [@CR9], [@CR19]--[@CR24]\].

If mutant distributed significantly more in non-CAD group than MACCE group, it was considered as a probably protective factor. If mutant distributed significantly less in non-CAD group than MACCE group, it was considered as a probably risk factor. Under this principle, the results showed: on *CDKN2B-AS1* gene, G mutant of rs1063192, A mutant of rs1333042, and G mutant of rs9632884 may be protective mutants, while G mutant of rs10757274, C mutant of rs1333049, and G mutant of rs4977574 may be risk mutants. In other words, the polymorphisms of *CDKN2B-AS1* gene were possibly associated with progression or suppression of TVD.

The *CDKN2B-AS1* gene, a gene cluster on 9p21.3, encodes a functional ribonucleic acid molecule, which causes epigenetic silencing on other genes. The mechanism how it involves in increased CAD onset risk remains unclear. A potential mechanism might be that expression of cell cycle inhibitor genes *CDKN2A* and *CDKN2B* was decreased and smooth muscle cell proliferation regulated by transcription factors expressed from risk alleles was accelerated \[[@CR8]\]. 9p21.3 was the first hereditary region identified, which was found closely associated with occurrence of CAD, independent of traditional risk factors, such as hyperlipidemia, hypertension and DM \[[@CR8], [@CR10], [@CR11], [@CR24]\]. It was reported that the risk alleles on 9p21.3 could indicate atherosclerotic plaque burden and predict severity of CAD \[[@CR25]\]. Interestingly, our study also found that in recessive model, the MACCE risk in patients with G mutant homozygous of rs9632884 (GG vs. GC + CC) was about 1/4 of whom with wild type homozygous or heterozygous. It indicated that *CDKN2B-AS1* gene on 9p21.3 not only related to onset risk and progression of atherosclerosis, but also suppression of coronary atherosclerosis worsening in TVD patients. Specific mechanism remains to be investigated.

Our study found that A mutant of rs1055432 on *ADAMTS13* gene and C mutant of rs8176694 on *ABO* gene showed a tendency of significant difference between the two groups*.* The *ADAMTS13* gene encodes von Willebrand factor (vWF) cleaving protease, named ADAMTS13, closely related to acute thrombosis. vWF is a glycoprotein in serum, thrombocytic granule, or on endothelial cell surface, synthesized and secreted by vascular endothelial cells and megakaryocytes. vWF participates in platelet adhesion and aggregation in combination with platelet membrane glycoprotein b and collagen at vascular lesions and stabilizes factor VIII activity by functioning as a carrier. Concentration of plasma ADAMTS13 decreases when vWF level increases during acute formation process of coronary thrombosis \[[@CR20], [@CR26], [@CR27]\]. A possible speculation of potential mechanism might be that A mutant causes expression reduction of *ADAMTS13*, thus vWF concentration increases, which promoted platelet adhesion and aggregation. *ABO* gene encodes ABO blood group antigens. An O-type blood-related variant might decrease the activity of glucosyl transferase, reduce concentration of vWF and factor VIII, and thus reduce risk of MI and venous thrombosis \[[@CR9], [@CR19]\]. C mutant of rs8176694 lies on an intron. Whether it only acts as a mark or plays a role in regulation of gene expression worth further discussion.

Data on genetic background of TVD is limited. A 15-year prospective study found that as well as age, increased body mass index, DM, low ejection fraction, left main artery stenosis, genetic variation in the interleukin-6 promoter were an independent risk factor for the survival of patients with TVD, contributing to understanding its role in the progression of atherosclerosis. However, none of the remaining 21 investigated polymorphisms constituted significant independent risk factors of death in patients suffering from TVD, although the association with CAD has been previously reported \[[@CR28]\]. Polymorphisms on *ADAMTS7, IL-18,* and *PECAM1* showed no significant difference between the two groups in our study, also inconsistent with data reported in CAD population. Therefore, although TVD is considered as the advanced stage of development of CAD, the genetic characteristics of TVD patients may be some different from whole CAD population.

Atherosclerotic plaque formation is the fundamental pathophysiological mechanism of CAD. Whether acute coronary syndrome generates, due to plaque vulnerability, may be the key determinant factor of prognosis of CAD patients. With the deepening of research, concepts of blood vulnerability and patient vulnerability were raised. Pathophysiological mechanisms cover genetic mechanisms, multiple traditional risk factors, clotting cascade, and inflammation mechanisms. Our results might add something new to era of "blood vulnerability" and "patient vulnerability". As genetic factors are irreversible, population with genetic variants may be treated with more aggressive strategy including first and second prevention, in common view of multifactorial pathogenesis. It also makes sense of prognostic valuation. Models within genetic variants for risk stratification in order to expand "area under curve" worth further research in precision medicine era \[[@CR29]--[@CR31]\].

Admittedly, the study has several limitations. Firstly, the relatively low number of control group reduced the power of the study. Secondly, it was considered as an "extreme population" study, in which it was much easier to find clues of genetic differences. Association found in case-control is weaker than prospective cohort study, which is being designed. Additionally, all patients were enrolled in single institution, mostly from the northern Han population, which limits the generalizability of our results. Nevertheless, this case-control study provides some new ideas on genetic factors which effect coronary atherosclerosis progression in Chinese TVD patients, in terms of both genetic and clinical data.

Conclusion {#Sec15}
==========

In patients with TVD in China, variant alleles on *CDKN2B-AS1* gene may form part of the genetic basis of coronary atherosclerosis progression, promoting or suppressing ischemic events.
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